Search the Newsreel

EXAGEN INC. Q2 2026: Revenue $19.94M, EPS $(0.13) — 10-Q Summary

EXAGEN INC. (XGN) reported its Q2 2026 financial results, showing revenue of $19.94 million and a diluted EPS of $(0.13). The company achieved a narrower net loss of $3.2 million compared to $4.44 million in the prior year, driven by improved margins, higher test …

Exagen Q2 2026 slides: record revenue, stock surges 36%

Exagen Inc. reported record revenue of $19.9 million for Q2 2026, marking 16% year-over-year growth and exceeding analyst expectations. The company's stock surged 35.9% following the announcement, driven by strong quarterly performance and raised full-year guidance. Exagen is nearing profitability, with adjusted EBITDA loss …

Exagen (NASDAQ:XGN) Beats Q2 Estimates and Raises Full-Year Guidance

Agenus Inc expected to post earnings of 5 cents a share - Earnings Preview

Agenus Inc is projected to report earnings of 5 cents per share. This information is presented as an earnings preview by Refinitiv, shared through TradingView News. The full article is available to subscribers of TradingView.

Exagen Reports Record Second-Quarter Revenue and Narrows Losses, Raises Full-Year 2026 Guidance

Exagen (XGN) announced record second-quarter 2026 revenue of $19.9 million, a 16% increase year-over-year. Despite a net loss of $3.2 million, the company raised its full-year 2026 revenue guidance to $72 million to $75 million. Insider trading data shows recent sales by executives, while …

Guggenheim cuts Ultragenyx stock price target on trial uncertainty

Guggenheim has reduced its price target for Ultragenyx Pharma (NASDAQ:RARE) shares from $43 to $35, while maintaining a Buy rating, due to uncertainty surrounding the company's ASPIRE study readout in Q3 2026. The firm notes that an overwhelmingly positive result could significantly boost the …

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen Inc. (Nasdaq: XGN) reported record total revenue of $19.9 million for the second quarter of 2026, a 16% increase year-over-year, and narrowed its adjusted EBITDA loss to $0.1 million. The company achieved a trailing twelve-month average selling price (ASP) of $446 for its …

Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview

Vistagen Therapeutics Inc is projected to report a loss of 36 cents per share, according to an earnings preview. The article indicates that this information is sourced from Refinitiv. Readers are prompted to access the full article through a paid subscription on TradingView.

IREDA Shares Fall 2% Despite Strong Q1 Profit Growth

Segall Bryant & Hamill LLC Lowers Holdings in Qiagen N.V. $QGEN

Segall Bryant & Hamill LLC reduced its stake in Qiagen N.V. by 24.5% in the first quarter, selling 36,110 shares but still retaining 111,177 shares worth approximately $4.45 million. Despite this reduction, other institutional investors like Groupe la Francaise, Janus Henderson Group PLC, Amundi, …

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen Inc. (XGN) reported a Q2 loss of $0.13 per share, exceeding the Zacks Consensus Estimate of a $0.19 loss and outperforming the prior year's loss of $0.18 per share. The company's revenues reached $19.94 million, surpassing the consensus estimate by 10.58% and the …

SRX Global acquires stake in Vistagen Therapeutics

SRX Global has acquired a minority equity stake in Vistagen Therapeutics, a Nasdaq-listed biotech company. The investment targets Vistagen's late-stage neuroscience pipeline, specifically its intranasal "pherine" product candidates. SRX Global believes Vistagen shares are undervalued and plans to engage with management and the board …

Niagen Bioscience (NAGE) Earnings Date and Reports 2026

Exagen (XGN) Stock Jumps On Record Revenue But Profit Timing Remains Unclear

Ultragenyx Pharmaceutical (RARE) Earnings Date and Reports 2026 $RARE

Qiagen NV expected to post earnings of 60 cents a share - Earnings Preview

Qiagen NV is projected to report earnings of 60 cents per share. This information comes from a Refinitiv earnings preview. The full article content is available on TradingView, which aggregates news from various sources including Reuters.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential securities claims against Agenus Inc. on behalf of investors who suffered losses exceeding $50,000 between January 23, 2023, and July 17, 2024. The investigation stems from allegations that Agenus made false or misleading statements regarding the effectiveness …

Ultragenyx (RARE) insider Howard Horn files to sell 4,696 shares

Ultragenyx Pharmaceutical Inc. insider Howard Horn has filed a Form 144 to sell 4,696 shares of common stock, valued at approximately $117,024.32. These shares were acquired as Restricted Stock and Performance Shares on March 1, 2025. The filing also indicates previous sales by Horn …

Niagen Bioscience (NAGE) FDA Approvals, PDUFA Dates & Drug Alerts 2026

Niagen Bioscience (NAGE) is advancing its drug candidate NB4168 for the treatment of Ataxia Telangiectasia. The company recently announced that it has selected Evotec as a contract research organization to support NB4168's development and previously received Rare Pediatric Disease designation from the FDA for …

Niagen Bioscience selects Evotec for rare disease drug studies

Niagen Bioscience has partnered with Evotec to support the development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease. Evotec will conduct pharmacokinetic and pharmacodynamic studies and validate bioanalytical methods for NB4168. Niagen Bioscience plans to submit an …

Evotec to Study NB4168 for Rare Pediatric Disease With No Approved Treatment

Niagen Bioscience has partnered with Evotec, a global life science company, to advance the preclinical development of NB4168, a proprietary oral small-molecule candidate for Ataxia Telangiectasia (A-T), a rare pediatric genetic disease with no approved treatments. Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies …

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Faruqi & Faruqi, LLP is investigating potential claims against Agenus Inc. (NASDAQ: AGEN) and is reminding investors of the November 5, 2024, deadline to seek the role of lead plaintiff in a federal securities class action. The investigation follows a significant drop in Agenus's …

IREDA Q1 Results 2027: Revenue Rises 16% YoY to ₹2,249 Cr, PAT Jumps 37% to ₹339 Cr

ADAG Q2 2025 Earnings: Wider EPS Miss Highlights Clinical-Stage Cash Burn - Final Results

IREDA Q1 Results: Net Profit Climbs 37% As Total Income Rises

IREDA Q1 Results Today: Time, Earnings Call, Dividend, What To Watch, Share Price

Q1 results 2026: IREDA to SBI Funds among companies to declare Q1 results today; full list here

IREDA Q1 Results: Net profit rises 37% YoY to ₹339 crore; asset quality stays stable

Q1 Results: DLF, SBI Funds Management, Jindal Stainless, IREDA, Torrent Power, Ather Energy, UPL, others to post earnings on August 3

Ralco Agencies Ltd. Revenue Breakdown – TASE:RLCO

Exagen (XGN) Q1 2026 Earnings: Narrower EPS Beat Overshadowed by 3% Share Decline - Quarterly Financial Update

VTGN Q2 2026 Earnings: EPS Miss of -$0.37 Highlights Continued Investment in Pre-Revenue Pipeline - EPS Surprise History

Exagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Qiagen N.V. $QGEN Shares Sold by Edgestream Partners L.P.

(RARE) Risk Channels and Responsive Allocation

This article analyzes Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) using AI models, indicating weak sentiment across all horizons which supports a short bias. It outlines three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional …

Ultragenyx Pharmaceutical, Inc. Revenue Breakdown – BX:UP0

Ultragenyx Pharmaceutical, Inc. (UP0) generated 533.53 million CHF in revenue last year, primarily from its Novel Products segment. The company's largest regional contribution came from North America, accounting for 298.87 million CHF. This financial overview highlights the company's key revenue drivers and geographical performance.